Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Oxybutynin hydrochloride 2.5 mg tablets
Medicines register · Ireland

Oxybutynin hydrochloride 2.5 mg tablets

Authorisation PA2315/038/001 · Accord Healthcare Ireland Ltd.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Accord Healthcare Ireland Ltd. (all products →)
Active substance
Oxybutynin hydrochloride
Clinical trials
6 clinical trials →
Dosage form
Tablet
Route of administration
Oral use
ATC codes
G04BD, G04BD04
First authorised
25/05/2012
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Oxybutynin hydrochloride: supply and approvals

4 authorised products on the HPRA list contain Oxybutynin hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 14 years (since 25 May 2012). The HPRA list marks it as marketed in Ireland.

Other medicines with Oxybutynin hydrochloride in Ireland

2 other products on the HPRA list contain Oxybutynin hydrochloride, from 2 licence holders; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Oxybutynin Hydrochloride 5mg TabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
KenteraTeva B.V.Centralised EU authorisationNot stated

Other substances in ATC group G04BD

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 10 other active substances share the group G04BD with this product:

Solifenacin succinate (18) · Tolterodine tartrate (8) · Propiverine hydrochloride (4) · Mirabegron (ym178) (2) · Trospium chloride (2) · Fesoterodine fumarate (2) · Darifenacin hydrobromide (1) · Oxybutynin (1) · Flavoxate hydrochloride (1) · Tamsulosin hydrochloride (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Accord Healthcare Ireland Ltd. holds 235 products on the HPRA list, with 112 different active substances; 137 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.